OTCMKTS:CHGCY Chugai Pharmaceutical Q4 2024 Earnings Report $21.05 +0.05 (+0.24%) As of 09/25/2026 03:59 PM Eastern ProfileEarnings HistoryForecast Chugai Pharmaceutical EPS ResultsActual EPS$0.18Consensus EPS N/ABeat/MissN/AOne Year Ago EPSN/AChugai Pharmaceutical Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AChugai Pharmaceutical Announcement DetailsQuarterQ4 2024Date1/30/2025TimeBefore Market OpensConference Call DateN/AConference Call TimeN/AUpcoming EarningsChugai Pharmaceutical's next earnings date is estimated for Friday, October 23, 2026, based on past reporting schedules. Conference Call ResourcesEarnings HistoryCompany Profile Chugai Pharmaceutical Earnings HeadlinesChugai Pharmaceutical (OTCMKTS:CHGCY) Hits New 12-Month Low - Should You Sell?September 18, 2026 | americanbankingnews.comChugai Pharmaceutical Co. Ltd. ADRAugust 19, 2026 | wsj.comMajor Buy Alert Issued for September 30thKeith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 people worldwide. His system has flagged a handful of stocks worth watching ahead of September 30th. See which stocks his AI research platform is flagging right now.September 26 at 1:00 AM | TradeSmith (Ad)Chugai Pharmaceutical Co., Ltd. (CHGCY) Q2 2026 Earnings Call TranscriptJuly 24, 2026 | seekingalpha.comChugai Pharmaceutical Co., Ltd. (CHGCY) Q4 2025 Earnings Call TranscriptJanuary 29, 2026 | seekingalpha.comChugai Reports Positive Data From TEIEN Study Of Port Delivery System With Ranibizumab In NAMD & DMENovember 25, 2025 | finanznachrichten.deSee More Chugai Pharmaceutical Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Chugai Pharmaceutical? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Chugai Pharmaceutical and other key companies, straight to your email. Email Address About Chugai PharmaceuticalChugai Pharmaceutical (OTCMKTS:CHGCY) Co., Ltd. is a Japan-based research-driven pharmaceutical company headquartered in Tokyo. Founded in 1925, the company focuses on discovering, developing, manufacturing and commercializing prescription medicines, with an emphasis on biotechnology and innovative therapies for serious and unmet medical needs. Chugai’s principal therapeutic areas include oncology, hematology, immunology, neuroscience and renal diseases. Its products include Actemra (known as RoActemra in some markets) for inflammatory and immune-related conditions, Hemlibra for hemophilia A, and Alecensa for certain forms of lung cancer. The company also develops antibody-based medicines and other biologic treatments using proprietary technologies. Chugai has a strategic alliance with Roche, which became its majority shareholder in 2002. Through this relationship, Chugai medicines are marketed in Japan and distributed internationally through Roche’s global network, while Chugai retains responsibility for its operations in Japan. The company is led by President and Chief Executive Officer Tatsuro Kosaka.View Chugai Pharmaceutical ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles MarketBeat Week in Review – 09/21 - 09/25Costco Ends Its Fiscal Year on a High Note, Eyes Big ExpansionCracker Barrel Stock Is Rallying Again, But the Turnaround Still Has a Traffic ProblemDarden Restaurants Serves Up Fresh Catalysts for a Stock Price RallySoFi Is Bypassing the Banking Bottleneck With Stablecoin SettlementSuper Micro’s Vera Rubin Shipments Put Its AI Infrastructure Advantage to the TestHims & Hers Slides Nearly 7% as Legal Pressure Adds to Its Growing List of Risks Upcoming Earnings Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026)The Goldman Sachs Group (10/13/2026)JPMorgan Chase & Co. (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
